Test Price
4,800 AED✅ Home Collection Available
Polycystic Kidney Disease Gene Panel in UAE | 4,800 AED | DHA-Licensed Genetic Testing
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9% sensitivity via ISO 9001:2015 accredited next-generation sequencing (NGS) platform.
Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM. Hospital extraction required for invasive prenatal specimens.
Post-Test Support: Telephonic result interpretation by a DHA-licensed Consultant Medical Genetics specialist.
Billing: Direct insurance verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Polycystic Kidney Disease (PKD) Gene Panel is a comprehensive next-generation sequencing (NGS) assay that analyses the full coding regions and splice sites of genes associated with autosomal dominant and autosomal recessive polycystic kidney disease. The panel interrogates PKD1, PKD2, PKHD1, GANAB, DNAJB11, and additional contiguous genes to detect pathogenic single-nucleotide variants, small insertions/deletions, and copy-number alterations. Results are reported with ACMG/AMP classification guidelines and require correlation with clinical history and renal imaging for definitive diagnosis.
| Feature | DNA Labs UAE – PKD Gene Panel | Alternative Approach (Imaging or Single-Gene) |
|---|---|---|
| Methodology | Next-Generation Sequencing (NGS) – multi-gene comprehensive analysis | Ultrasound / MRI (anatomical only) or PCR-based single-gene test |
| Genes Covered | PKD1, PKD2, PKHD1, GANAB, DNAJB11, and additional syndromic loci | Limited to one gene or anatomical evaluation only |
| Turnaround Time | 4–6 weeks | Immediate (imaging) or 2–3 weeks (single-gene) |
| Price (AED) | 4,800 AED | Variable; often partial insurance coverage for genetic testing |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
"The PKD gene panel provides a critical molecular diagnosis for individuals with a strong family history of renal cystic disease. Identifying the causative variant enables tailored surveillance for extra-renal manifestations, informs recurrence risk counselling for family planning, and may guide eligibility for targeted therapies in select cases. Results must always be interpreted alongside renal imaging and a complete clinical assessment. Patients should continue all prescribed medications and consult their nephrologist before making any treatment changes."
Advisory – Clinical Safety Precaution
This test is designed for heritable renal cystic disease evaluation and is not indicated for the assessment of acute kidney injury, obstructive uropathy, or acquired cystic disease. Do not discontinue or modify any prescribed medication based solely on genetic results without explicit guidance from your treating physician.
Exclusion Criteria & Emergency Indicators
- This panel does not replace renal biopsy or acute clinical management protocols.
- Invasive prenatal sampling (amniocentesis or chorionic villus sampling) must be performed under ultrasound guidance in an accredited hospital setting; mobile home collection is disabled for these procedures.
- Seek immediate emergency care for sudden severe flank pain, visible hematuria, fever with rigors, or acute urinary retention.
- A signed referral from a DHA-licensed physician is required prior to sample collection, except as permitted for preventive genetic screening under applicable regulations.
Patient FAQ & Clinical Guidance
1. What does the Polycystic Kidney Disease Gene Panel detect?
This NGS panel identifies pathogenic variants in PKD1, PKD2, PKHD1, and other genes associated with autosomal dominant and recessive polycystic kidney disease. It confirms a clinical diagnosis, predicts disease progression patterns, and enables cascade screening for at-risk relatives. Results must be interpreted alongside renal imaging and reviewed with a genetics specialist.
2. How is the sample collected for this genetic test?
For adults and children, a standard peripheral whole blood sample is drawn via VIP Mobile Phlebotomy during a scheduled home visit. For prenatal diagnosis, amniotic fluid or chorionic villus sampling is performed strictly within a hospital setting under ultrasound guidance by an experienced maternal-fetal medicine specialist. All specimens are transported using validated temperature-controlled cold-chain logistics to preserve nucleic acid integrity.
3. Is the test compliant with UAE regulatory standards for genetic testing?
Yes. The test is developed and validated under ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) and performed at our DHA-licensed facility (License No. 1143) in Dubai Healthcare City. Data handling adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Governance: All genetic data generated by this panel is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent, sample handling, and result disclosure follow the provisions of Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory operates under DHA Facility License No. 1143 and maintains ISO 9001:2015 accreditation. No genetic information is shared with third parties without explicit written consent from the patient or legal guardian.
Clinical & Logistical Metadata
| Test Name | Polycystic Kidney Disease Gene Panel |
| Price (AED) | 4,800 AED |
| Turnaround Time | 4–6 weeks |
| Sample Type / Matrix | Peripheral whole blood (adults/children); amniotic fluid or chorionic villus (prenatal – hospital extraction only) |
| Methodology Used | Next-Generation Sequencing (NGS) – full coding region and splice site analysis |
| ICD-10-CM Code | Q61.3 (Polycystic kidney, unspecified) |
| LOINC Code | 94038-6 |
| DHA Facility License & Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians